Overview

UBT251 Injection Phase II Clinical Study (CKD)

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2030-07-11

Target enrollment:

Participant gender:

Summary

This multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of UBT251 injection in obese/overweight chronic kidney disease (CKD) population

Phase:

PHASE2

Details

Lead Sponsor:

The United Bio-Technology (Hengqin) Co., Ltd.